Ponce DM, Alousi AM, Nakamura R, et al. A Phase 2 Study of Interleukin-22 and Systemic Corticosteroids as Initial Treatment for Acute GVHD of the Lower GI Tract. Blood. 2022; (doi: 10.1182/blood.2021015111).
Research shows that use of F-652, a novel recombinant human Interleukin-22 dimer, with systemic corticosteroids appears to be safe and linked to a high response rate for the initial treatment of acute graft versus host disease (GVHD) of the lower gastrointestinal tract. The single-arm, Phase II study included 27 patients. There were no dose-limiting toxicities associated with the treatment. Cytopenias and electrolyte abnormalities were the most frequent adverse events following treatment. Overall, 70% (N=19) of the patients met the primary endpoint of treatment response by day 28. In those patients, the fecal microbiota composition was marked by growth of commensal anaerobes. This corresponded with higher overall microbial a-diversity. Researchers concluded that combining immunosuppression with tissue-supportive strategies enhanced recovery of damaged mucosa and promoted microbial health in patients with gastrointestinal GVHD.
Tags: study, GVHD, Treatment, response, Acute GVHD, researchers, graft-versus-host disease, graft-vs-host disease, graft-versus-host